Clinical Trial

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-04 -> 2027-05-31 2026-08-11
minor Completion pushed: 2027-04 -> 2027-05-31 2026-08-11
Trial Details
NCT Number NCT05531656
Lead Sponsor Cognition Therapeutics
Collaborators: National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Conditions Early Alzheimer's Disease
Enrollment 540 participants
Start Date 2023-06-28
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10